tetano
Editor, Senior Moderator
Panminerva Med
. 2020 Jun 16.
doi: 10.23736/S0031-0808.20.03999-3. Online ahead of print.
The Thromboembolism in COVID-19: The Unsolved Problem
Matteo Casale[SUP] 1 [/SUP], Giuseppe Dattilo[SUP] 2 [/SUP], Egidio Imbalzano[SUP] 2 [/SUP], Marianna Gigliotti De Fazio[SUP] 2 [/SUP], Claudia Morabito[SUP] 2 [/SUP], Maurizio Mezzetti[SUP] 1 [/SUP], Paolo Busacca[SUP] 1 [/SUP], Salvatore S Signorelli[SUP] 3 [/SUP], Natale D Brunetti[SUP] 4 [/SUP], Michele Correale[SUP] 5 [/SUP]
Affiliations
Abstract
Introduction: The recent Sars-Cov-2 pandemic (COVID-19) has led to growing research to explain the poor clinical prognosis in some patients.
Evidence acquisition: While early observational studies highlighted the role of the virus in lung failure, in a second moment thrombosis emerged as a possible explanation of the worse clinical course in some patients. Despite initial difficulties in management of such patients, the constant increase of literature in the field is to date clarifying some questions from clinicians. However, several other questions need answer.
Evidence synthesis: A novel disease (Covid-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was responsible for thousands of hospitalizations for severe acute respiratory syndrome, with several cases of thrombotic complications due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. Covid-19 and hospitalizations for Covid-19 may carry several potential risk factors for thrombosis. Severe coagulation abnormalities may occur in almost all of the severe and critical ill COVID-19 cases.
Conclusions: Despite a strong pathophysiological rationale, the evidences in literature are not enough to recommend an aggressive antithrombotic therapy in COVID- 19. However, it is our opinion that an early use, even at home at the beginning of the disease, could improve the clinical course.
. 2020 Jun 16.
doi: 10.23736/S0031-0808.20.03999-3. Online ahead of print.
The Thromboembolism in COVID-19: The Unsolved Problem
Matteo Casale[SUP] 1 [/SUP], Giuseppe Dattilo[SUP] 2 [/SUP], Egidio Imbalzano[SUP] 2 [/SUP], Marianna Gigliotti De Fazio[SUP] 2 [/SUP], Claudia Morabito[SUP] 2 [/SUP], Maurizio Mezzetti[SUP] 1 [/SUP], Paolo Busacca[SUP] 1 [/SUP], Salvatore S Signorelli[SUP] 3 [/SUP], Natale D Brunetti[SUP] 4 [/SUP], Michele Correale[SUP] 5 [/SUP]
Affiliations
- PMID: 32549531
- DOI: 10.23736/S0031-0808.20.03999-3
Abstract
Introduction: The recent Sars-Cov-2 pandemic (COVID-19) has led to growing research to explain the poor clinical prognosis in some patients.
Evidence acquisition: While early observational studies highlighted the role of the virus in lung failure, in a second moment thrombosis emerged as a possible explanation of the worse clinical course in some patients. Despite initial difficulties in management of such patients, the constant increase of literature in the field is to date clarifying some questions from clinicians. However, several other questions need answer.
Evidence synthesis: A novel disease (Covid-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was responsible for thousands of hospitalizations for severe acute respiratory syndrome, with several cases of thrombotic complications due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. Covid-19 and hospitalizations for Covid-19 may carry several potential risk factors for thrombosis. Severe coagulation abnormalities may occur in almost all of the severe and critical ill COVID-19 cases.
Conclusions: Despite a strong pathophysiological rationale, the evidences in literature are not enough to recommend an aggressive antithrombotic therapy in COVID- 19. However, it is our opinion that an early use, even at home at the beginning of the disease, could improve the clinical course.